Keyphrases
Live Attenuated
100%
Preclinical Evaluation
100%
Chikungunya Virus (CHIKV)
100%
Chikungunya Vaccine
100%
Virus Vaccine
40%
Public Health
20%
Complementary DNA (cDNA)
20%
Vaccine Strain
20%
Fever
20%
Preclinical Development
20%
Immunogenic
20%
Internal Ribosome Entry Site
20%
Structural Protein Genes
20%
Encephalomyocarditis Virus
20%
Mosquito Vectors
20%
Clinical Testing
20%
Human Trials
20%
Nonhuman Primate
20%
Arthritis
20%
Mandatory Vaccines
20%
Africa
20%
Subgenomic Promoter
20%
Travellers
20%
Italy
20%
Development Effort
20%
South-East Asia
20%
Indian Subcontinent
20%
Highly Stable
20%
Synonymous mutation
20%
Investigational New Drug
20%
Attenuation Mechanism
20%
Medicine and Dentistry
Chikungunya
100%
Chikungunya Virus
100%
Virus Vaccine
40%
Public Health
20%
Infection
20%
Promoter Region
20%
Complementary DNA
20%
Mosquito Vector
20%
Structural Protein
20%
Internal Ribosome Entry Site
20%
Vaccine Strain
20%
Arthritis
20%
Encephalomyocarditis Virus
20%
Attenuation Mechanisms
20%
Pre-Clinical Development
20%
Pharmacology, Toxicology and Pharmaceutical Science
Chikungunya
100%
Chikungunya Virus
100%
Virus Vaccine
40%
Infection
20%
Vaccine Strain
20%
Structural Protein
20%
Complementary DNA
20%
Mosquito Vector
20%
Arthritis
20%
Encephalomyocarditis Virus
20%
Immunology and Microbiology
Chikungunya Virus
100%
Virus Vaccine
40%
Promoter Region
20%
Preclinical Study
20%
Encephalomyocarditis Virus
20%
Internal Ribosome Entry Site
20%
Arthritis
20%
Biochemistry, Genetics and Molecular Biology
Chikungunya Virus
100%
Promoter Region
20%
Structural Protein
20%
Internal Ribosome Entry Site
20%
Encephalomyocarditis Virus
20%
Preclinical Study
20%
Attenuation Mechanisms
20%